Simplify Asset Management Inc. Has $3.04 Million Stake in Milestone Pharmaceuticals Inc. $MIST

Simplify Asset Management Inc. trimmed its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 46.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,506,405 shares of the company’s stock after selling 1,326,569 shares during the quarter. Simplify Asset Management Inc.’s holdings in Milestone Pharmaceuticals were worth $3,043,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Strategic Family Wealth Counselors L.L.C. bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth $25,000. Bank of America Corp DE grew its holdings in Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after buying an additional 16,044 shares in the last quarter. Creative Planning grew its holdings in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after buying an additional 10,000 shares in the last quarter. Bay Rivers Group grew its holdings in Milestone Pharmaceuticals by 72.9% during the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after buying an additional 12,170 shares in the last quarter. Finally, Raymond James Financial Inc. grew its holdings in Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after buying an additional 10,000 shares in the last quarter. Institutional investors own 86.18% of the company’s stock.

Analysts Set New Price Targets

MIST has been the subject of several recent research reports. Zacks Research downgraded Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, May 15th. Raymond James Financial initiated coverage on Milestone Pharmaceuticals in a report on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price target for the company. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Finally, Wells Fargo & Company reduced their price objective on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.25.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST opened at $1.41 on Monday. The company has a market capitalization of $175.55 million, a PE ratio of -2.07 and a beta of 1.04. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.18 and a quick ratio of 9.09. The business has a fifty day moving average price of $1.68 and a two-hundred day moving average price of $1.91. Milestone Pharmaceuticals Inc. has a 1 year low of $1.00 and a 1 year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.12 million. Analysts forecast that Milestone Pharmaceuticals Inc. will post -0.97 earnings per share for the current year.

Insider Activity at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 36,500 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $2.26, for a total transaction of $82,490.00. Following the transaction, the chief executive officer owned 446,244 shares of the company’s stock, valued at $1,008,511.44. This represents a 7.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.50% of the stock is owned by corporate insiders.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.